A randomized double-blind, non-inferiority Phase II trial, comparing dapaconazole tosylate 2% cream with ketoconazole 2% cream in the treatment of Pityriasis versicolor

Bibliography

• Faergemann J, Fredriksson T. Tinea versicolor: some new aspects on etiology, pathogenesis, and treatment. Int J Dermatol 1982;21(1):8–11
   PubMed Web of Science ®Google Scholar
• Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002;16(1):19–33
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12(4):501–17
   PubMed Web of Science ®Google Scholar
• Miranda KC, de Araujo CR, Costa CR, et al. Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents 2007;29(3):281–4
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Kano R, Murai T, et al. Susceptibility testing of Malassezia species using the urea broth microdilution method. Antimicrob Agents Chemother 2000;44(8):2185–6
   PubMed Web of Science ®Google Scholar
• Garau M, Pereiro MJr, del Palacio A. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob Agents Chemother 2003;47(7):2342–4
   PubMed Web of Science ®Google Scholar
• Kepler AF, Sacurai SL, Zaim MH, et al. Benzyl aralkyl ether com-pounds, method for preparing same, intermediate compounds, use of said compounds, method for treatment and/or prevention, pharmaceutical composition and medicament containing same. WO2011022798; 2012. Available from: http://worldwide.espacenet.com/publicationDetails/originalDocument?CC=US&NR=2012196908A1&KC=A1&FT=D&ND=3&date=20120802&DB=worldwide.espacenet.com&locale=en%20EP [Last accessed 05 January 2015]
   Google Scholar
• de Moraes FC, Bittencourt SF, Perissutti E, et al. Quantification of dapaconazole in human plasma using high-performance liquid chromatography coupled to tandem mass spectrometry: application to a phase I study. J Chromatogr B Analyt Technol Biomed Life Sci 2014;958:102–7
   PubMed Web of Science ®Google Scholar
• Gagliano-Jucá T, Arruda AMM, Sampaio MF, et al. Phase I Study of the Novel Antifungal Agent Dapaconazole (Zilt®) in Healthy Volunteers. Int J Pharmacol 2014;10(8):507–12
   Google Scholar
• Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21(3):247–54
   PubMed Web of Science ®Google Scholar
• Yim SM, Ko JH, Lee YW, et al. Study to compare the efficacy and safety of fluconazole cream with flutrimazole cream in the treatment of superficial mycosis: a multicentre, randomised, double-blind, phase III trial. Mycoses 2010;53(6):522–9
   PubMed Web of Science ®Google Scholar
• Sharma A, Saple DG, Surjushe A, et al. Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. Mycoses 2011;54(3):217–22
   PubMed Web of Science ®Google Scholar
• Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol 2007;46(5):947–54
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ 1998;317(7172):1572
   PubMed Web of Science ®Google Scholar
• Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of Tinea versicolor. J Am Acad Dermatol 1986;15(3):500–3
   PubMed Web of Science ®Google Scholar
• Balwada RP, Jain VK, Dayal S. A double-blind comparison of 2% ketoconazole and 1% clotrimazole in the treatment of Pityriasis versicolor. Indian J Dermatol Venereol Leprol 1996;62(5):298–300
   PubMedGoogle Scholar
• Chopra V, Jain VK. Comparative study of topical terbinafine and topical ketoconazole in Pityriasis versicolor. Indian J Dermatol Venereol Leprol 2000;66(6):299–300
   PubMedGoogle Scholar
• Choudhary S, Bisati S, Singh A, et al. Efficacy and Safety of Terbinafine Hydrochloride 1% Cream vs. Sertaconazole Nitrate 2% Cream in Tinea Corporis and Tinea Cruris: A Comparative Therapeutic Trial. Indian J Dermatol 2013;58(6):457–60
   PubMedGoogle Scholar
• Jerajani H, Janaki C, Kumar S, et al. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol 2013;58(1):34–8
   PubMedGoogle Scholar
• Nasarre J, Umbert P, Herrero E, et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of Pityriasis versicolor. Arzneimittelforschung 1992;42(5A):764–7
   PubMed Web of Science ®Google Scholar
• Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatol 1989;14(2):114–15
   PubMed Web of Science ®Google Scholar
• Watanabe S, Takahashi H, Nishikawa T, et al. A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for Tinea pedis. Mycoses 2006;49(3):236–41
   PubMed Web of Science ®Google Scholar
• Watanabe S, Takahashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for Tinea pedis–comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses 2007;50(1):35–40
   PubMed Web of Science ®Google Scholar
• Feng X, Xie J, Zhuang K, et al. Efficacy and tolerability of luliconazole cream 1% for dermatophytoses: a meta-analysis. J Dermatol 2014;41(9):779–82
   PubMed Web of Science ®Google Scholar
• Czaika V, Nenoff P, Glockner A, et al. Detection of azole susceptibility patterns in clinical yeast strains isolated from 1998 to 2008. New Microbiol 2014;37(4):465–94
   PubMed Web of Science ®Google Scholar